This post was just published on ZYX Short Sell Change Alert. PTCT is short from $56.42. As of this writing it is trading at $47.33. Consider taking profits and exiting the position. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A
This post was just published on ZYX Short Sell Change Alert. PTCT is short from $56.42. 20% of the full core position size is being held. As of this writing the stock is trading at $49.24. Consider taking profits on a 10% tranche in the zone of $47. to $49.36. After
This post was just published on ZYX Short Change Alert. Consider taking partial profits on a 25% tranche of PTCT in the zone of $50.61 to $53.31. As of this writing it is trading at $53.13 in the premarket. Consider continuing to hold the remaining 20%. You are receiving less than
This post was just published on ZYX Short Change Alert. Consider exiting a 10% tranche on PTCT in the zone of $56. to $59.15. Consider continuing to hold the remaining 45%. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL
This post was just published on ZYX Short Change Alert. PTCT has spiked on rumors of takeout. There is a reasonable probability that these rumors are wrong. Consider adding a 15% tranche in the zone of $67 to $70.73 if still holding. The stock is trading at $67.72 as of this
This post was just published on ZYX Short Change Alert. Shortly after 11:30 AM PTCT began running up on a buyout rumor. With its clinical trials halted, the stock should have fallen into the $30’s, the timing of the rumor is suspect. It is not uncommon for unsavory characters to spread false
This post was just published on ZYX Short Change Alert. Consider changing the stop zone to a mental zone of $53.33 – 53.87. Also consider adding a 10% tranche in the zone of $ 51.73 -52.73. You are receiving less than 2% of the content from our paid services …TO RECEIVE
This post was just published on ZYX Short Change Alert. There are reports from England of issues with a promising drug trial for duchenne muscular dystrophy. If the rumors are true, the stock can easily fall to $30 to $37. Consider short selling up to 30% of the full core position size in
This post was just published on ZYX Short Change Alert. RNA is again falling to under $10. Mental stop zone now is $14.00 15.56. This is a very volatile stock suitable only for aggressive investors. Target zone is $4.00-4.50. The probability of its treatment ultimately getting approval is small. What to
This post was just published on ZYX Short Change Alert. RNA is a development stage biotech company. Until yesterday shares had moved up in sympathy with the success at PTCT. Today’s shares are moving up strongly again as investors react to company releasing its presentation to be made at Jeffries on